44:I[185,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SendEmailButton"] 46:I[63625,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"AddToLibraryButton"] 47:I[29721,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ShareButton"] 48:I[58016,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"ProcessEpisodeButton"] 49:I[45269,["/_next/static/chunks/08z4tkzvltetr.js","/_next/static/chunks/121~yigv24_j6.js","/_next/static/chunks/0jo3du-icy6v2.js","/_next/static/chunks/15cy49d~_zsjj.js","/_next/static/chunks/0..ktetnpeix7.js","/_next/static/chunks/0_htf5~kl..m1.js","/_next/static/chunks/0i6hzvr84kc1r.js"],"SignupCTA"] 3b:["$","time",null,{"dateTime":"2026-05-19T10:00:04.000Z","children":"May 19, 2026"}] 3c:["$","span",null,{"aria-hidden":true,"children":"·"}] 3d:["$","span",null,{"children":"00:02:24"}] 3e:["$","p",null,{"className":"max-w-[60ch] text-[18px] leading-[1.5] text-[color:var(--fg-2)]","children":"Is a new era of targeted cancer therapy finally here? In today’s episode, we analyze the landmark results from the Phase 3 TroFuse-005 trial, which could redefine the standard of care for women with advanced or recurrent endometrial cancer. We break..."}] 45:T479,Is a new era of targeted cancer therapy finally here? In today’s episode, we analyze the landmark results from the Phase 3 TroFuse-005 trial, which could redefine the standard of care for women with advanced or recurrent endometrial cancer. We break down how sacituzumab tirumotecan (sac-TMT), an investigational TROP2-directed ADC, achieved a statistically significant improvement in both overall survival (OS) and progression-free survival (PFS) compared to standard chemotherapy.

We dive into the science of how this "targeted missile" delivers a toxic payload directly to tumor cells while sparing healthy tissue. With endometrial cancer rates rising globally, we explore why this first positive win for the broader TroFuse program is a game-changer for patients who have already exhausted platinum-based chemo and immunotherapy. Plus, we discuss the FDA’s Priority Voucher that could fast-track this drug to the market. Join us as we explore what this means for the future of oncology and Merck’s $70 billion sales goal.

This episode includes AI-generated content.